European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab)
European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent (alirocumab)
- Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab)
- Praluent (alirocumab) continues to be available in European countries where it is approved for use and for sale
PARIS – October 29, 2020 – The European Patent Office (EPO) Technical Boards of Appeal has today ruled in Sanofi and Regeneron’s favor, invalidating certain claims of Amgen’s European patent (EP 2 215 124) directed to PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies relevant to Praluent (alirocumab). Praluent will continue to be available in European countries where it is approved for use and for sale.
“We are pleased with today’s decision by the European Patent Office, which upholds the rigorous standard for pharmaceutical patents that we argued for in this case, affirming that Amgen’s asserted claims against Sanofi in Europe are invalid,” said Karen Linehan, Executive Vice President, Legal Affairs and General Counsel, Sanofi. “This decision validates our years-long commitment to vigorously defending this case.”
Today's EPO decision follows a ruling in Sanofi and Regeneron’s favor in August 2019 by the U.S. District Court for the District of Delaware which found as a matter of law that certain of Amgen’s asserted patent claims for antibodies targeting PCSK9 are invalid based on lack of enablement.
Editor’s notes
Under a restructured agreement announced in December 2019, Sanofi
possesses sole rights for Praluent outside the U.S. Regeneron has sole rights for Praluent inside the U.S. Each party is solely responsible for funding development and commercialization expenses in
their respective territories.
Praluent is not available in Germany, following an injunction granted by the Düsseldorf Regional Court in July 2019. Sanofi has appealed this decision, and a hearing for the appeal is scheduled for November 5, 2020.
Lesen Sie auch
About Praluent
Praluent (alirocumab) inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the low-density lipoprotein (LDL) receptor and thereby increases the number of available LDL
receptors on the surface of liver cells to clear LDL, which lowers LDL cholesterol (LDL-C) levels in the blood. Praluent was developed by Sanofi and Regeneron under a global collaboration
agreement.